A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2018
At a glance
- Drugs AMG 427 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 16 Nov 2018 Planned End Date changed from 20 Aug 2020 to 9 Jan 2021.
- 16 Nov 2018 Planned primary completion date changed from 20 Aug 2020 to 9 Jan 2021.
- 09 Oct 2018 Status changed from not yet recruiting to recruiting.